Senya Therapeutics is pioneering an anti-leucine-rich α-2 glycoprotein 1 (LRG1) therapeutic platform. The protein, and its role in neovascularisation in the retina, was described by Senya’s founders Professors Greenwood and Moss at the UCL Institute of Ophthalmology. It has since been shown to be involved in the progression of numerous human conditions, including cancer, diabetes, cardiovascular disease, neurological disease, and inflammatory disorders. Therefore, targeting LRG1 offers a new way to treat chronic diseases.

Senya holds the global patent rights for LRG1 as a therapeutic target and is currently focusing its research efforts into unmet clinical needs in nephrology and oncology.

The company was initially founded as LRG1 in 2019.